[Comment] Lung cancer's real adjuvant EGFR targeted therapy questions

In The Lancet Oncology, Wen-Zhao Zhong and colleagues report findings of the ADJUVANT study.1 222 patients with completely resected, stage II –IIIA (N1–N2), EGFR-mutant non-small-cell lung cancer (NSCLC) were randomly assigned to either four cycles of adjuvant vinorelbine plus cisplatin or 24 months of gefitinib—an EGFR tyrosine kinase inhibitor. Disease-free survival (the primary endpoint) was significantly longer for patients assi gned gefitinib than for those assigned cisplatin-based chemotherapy (median 28·7 months, 95% CI 24·9–32·5 vs 18·0 months, 13·6–22·3; hazard ratio [HR] 0·60, 95% CI 0·42–0·87; p=0·0054).

Source: The Lancet Oncology - November 21, 2017 Category: Cancer & Oncology Authors: Terry L Ng, D Ross Camidge Tags: Comment Source Type: research